CRISPR Therapeutics AG — Director's Dealing 2021

Mar 9, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CRISPR Therapeutics AG (CRSP)
CIK: 0001674416
Period of Report: 2021-03-05

Reporting Person: Ho Tony W (Executive VP, Head of R&D)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-03-05	Common Shares	M	3333	—	Acquired	37447	Direct
2021-03-05	Common Shares	F	1585	$114.65	Disposed	35862	Direct

Footnotes

F1: On March 5, 2019, the reporting person was granted 10,000 restricted stock units. On March 5, 2021, 3,333 restricted stock units vested.

F2: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

F3: Includes 150 shares acquired under the CRISPR Therapeutics AG 2016 Employee Stock Purchase Plan.

F4: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.